FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Steven Weitman

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Tumor Cells, Cultured

Living Beings

Concepts & Ideas

Procedures

Physiology

Drug Resistance, Neoplasm

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Chun-Liang Chen; Maria Gaczynska; Tien-Cheng Chang; Rohit R Jadhav; Addanki Pratap Kumar; Robin J Leach; Devalingam Mahalingam; Pawel Osmulski; Luzhe Sun; Ian M Thompson; Chiou-Miin Wang; Steven D Weitman; Tim Hui-Ming Huang
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
Peter L Bonate; Casey C Cunningham; Paul S Gaynon; Sima Jeha; Richard Kadota; Gilbert N Lam; Bassem I Razzouk; Michael Rytting; Peter G Steinherz; Steven D Weitman
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Francesco Caponigro; D Lorusso; G Fornari; C Barone; Marco Merlano; M Airoldi; M Schena; R MacArthur; Steven D Weitman; M G Jannuzzo; S Crippa; F Fiorentini; A Petroccione; S Comis
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Steven Weitman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Chun-Liang Chen; Maria Gaczynska; Tien-Cheng Chang; Rohit R Jadhav; Addanki Pratap Kumar; Robin J Leach; Devalingam Mahalingam; Pawel Osmulski; Luzhe Sun; Ian M Thompson; Chiou-Miin Wang; Steven D Weitman; Tim Hui-Ming Huang
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
The Prostate 2013;73(8):813-26.
2011: Peter L Bonate; Casey C Cunningham; Paul S Gaynon; Sima Jeha; Richard Kadota; Gilbert N Lam; Bassem I Razzouk; Michael Rytting; Peter G Steinherz; Steven D Weitman
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Cancer chemotherapy and pharmacology 2011;67(4):875-90.
2010: Francesco Caponigro; D Lorusso; G Fornari; C Barone; Marco Merlano; M Airoldi; M Schena; R MacArthur; Steven D Weitman; M G Jannuzzo; S Crippa; F Fiorentini; A Petroccione; S Comis
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2010;66(2):389-94.
2007: D R Mould; A Baumann; J Kuhlmann; M J Keating; Steven D Weitman; Peter Hillmen; Lee R Brettman; S Reif; Peter L Bonate
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.
British journal of clinical pharmacology 2007;64(3):278-91.
2006: Peter L Bonate; Larry Arthaud; William R Cantrell; Katherine Stephenson; John A Secrist; Steven D Weitman
Discovery and development of clofarabine: a nucleoside analogue for treating cancer.
Nature reviews. Drug discovery 2006;5(10):855-63.
2006: Catalin Mita; Lisa A Hammond; Peter L Bonate; Geoffrey Weiss; Heather McCreery; Samira Syed; Mitchell Garrison; Quincy S C Chu; Johann S DeBono; Christopher B Jones; Steven D Weitman; Eric K Rowinsky
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5207-15.
2006: Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven D Weitman; Peter G Steinherz
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1917-23.
2005: Naoki Agata; Hiroko Nogi; Michael Bamberg; Michael Milhollen; Minying Pu; Steven D Weitman; Surender Kharbanda; Donald Kufe
The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Cancer chemotherapy and pharmacology 2005;56(6):610-4.
2005: Casey Cunningham; Leonard J Appleman; Miora Kirvan-Visovatti; David P Ryan; Eileen Regan; Svetislava Vukelja; Peter L Bonate; Francis Ruvuna; Robert J Fram; Antti Jekunen; Steven D Weitman; Lisa A Hammond; Joseph P Eder
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7825-33.
2005: Scot W Ebbinghaus; Eric Rubin; Evan M Hersh; Lee D Cranmer; Peter L Bonate; Robert J Fram; Antti Jekunen; Steven D Weitman; Lisa A Hammond
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7807-16.
2005: Terzah M Horton; Susan M Blaney; Anne-Marie Langevin; John Kuhn; Barton A. Kamen; Stacey L Berg; Mark Bernstein; Steven D Weitman
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1884-9.
2005: Seth J Corey; Marily Elopre; Steven D Weitman; Michael Rytting; Lisa J Robinson; Steve Rumelhart; Frederick D Goldman
Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia.
Journal of pediatric hematology/oncology 2005;27(3):166-8.
2004: Peter L Bonate; Adam Craig; Paul S Gaynon; Varsha Gandhi; Sima Jeha; Richard Kadota; Gilbert N Lam; William Plunkett; Bassem I Razzouk; Michael Rytting; Peter G Steinherz; Steven D Weitman
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
Journal of clinical pharmacology 2004;44(11):1309-22.
2004: Emily S Van Laar; Elzbieta Izbicka; Steven D Weitman; Leticia Medina-Gundrum; John R MacDonald; Stephen J Waters
Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(5):824-31.
2004: Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steven D Weitman; Kenneth W Wood
Antitumor activity of a kinesin inhibitor.
Cancer research 2004;64(9):3276-80.
2004: Victor M Aquino; Steven D Weitman; Naomi J Winick; Susan Blaney; Wayne L Furman; James L Kepner; Peter L Bonate; Mark Krailo; Wenchun Qu; Mark Bernstein
Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1413-9.
2004: Emily S Van Laar; Steven D Weitman; John R MacDonald; Stephen J Waters
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
The Prostate 2004;59(1):22-32.
2004: Emily S Van Laar; Stephanie Roth; Steven D Weitman; John R MacDonald; Stephen J Waters
Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Anticancer research 2004;24(1):59-65.
2003: Barbara A Gruner; Thomas S DeNapoli; Said Elshihabi; Howard A Britton; Anne-Marie Langevin; Paul Thomas; Steven D Weitman
Anemia and hepatosplenomegaly as presenting features in a child with rickets and secondary myelofibrosis.
Journal of pediatric hematology/oncology 2003;25(10):813-5.
2003: Robert J Hayashi; Susan Blaney; Jim Sullivan; Steven D Weitman; Teresa J Vietti; Mark L Bernstein
Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study.
Journal of pediatric hematology/oncology 2003;25(7):539-42.
2003: Anne-Marie Langevin; Steven D Weitman; John Kuhn; Susan Weintraub; Sylvain Baruchel; Wayne L Furman; Mark Bernstein; Susan Blaney; Teresa J Vietti
Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study.
Journal of pediatric hematology/oncology 2003;25(7):526-33.
2003: Leticia Medina-Gundrum; Cesario Cerna; Lionel R Gomez; Michael Yochmowitz; Steven D Weitman
AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients.
Anti-cancer drugs 2003;14(4):275-80.
2003: Lee Jia; Hong Wong; Yao Wang; Mark Garza; Steven D Weitman
Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle.
Journal of pharmaceutical sciences 2003;92(1):161-72.
2002: Jian Ling; Steven D Weitman; Michael A Miller; Rodney V Moore; Alan C Bovik
Direct Raman imaging techniques for study of the subcellular distribution of a drug.
Applied optics 2002;41(28):6006-17.
2002: Lee Jia; Hong Wong; Cesario Cerna; Steven D Weitman
Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry.
Pharmaceutical research 2002;19(8):1091-6.
2002: Desirée Hao; Jinee D Rizzo; Stephanie Stringer; Rodney V Moore; Jennifer Marty; Daniel L Dexter; Gina L Mangold; Jim B Camden; Daniel Von Hoff; Steven D Weitman
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).
Investigational new drugs 2002;20(3):261-70.
2002: Cory L Grand; Haiyong Han; Rubén M Muñoz; Steven D Weitman; Daniel Von Hoff; Laurence H Hurley; David J Bearss
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.
Molecular cancer therapeutics 2002;1(8):565-73.
2002: Daekyu Sun; Rheanna Urrabaz; Susan Kelly; Myhanh Nguyen; Steven D Weitman
Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1189-95.
2002: Lee Jia; Mark Garza; Hong Wong; Dody Reimer; Thomas Redelmeier; Jim B Camden; Steven D Weitman
Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice.
Journal of pharmaceutical and biomedical analysis 2002;28(1):65-72.
2001: H Wong; L Jia; Jim B Camden; Steven D Weitman
Liquid chromatography-mass spectrometry assay of a thiadiazole derivative in mice: application to pharmacokinetic studies.
Journal of chromatography. B, Biomedical sciences and applications 2001;765(1):55-62.
2001: Daekyu Sun; Rheanna Urrabaz; Myhanh Nguyen; J Marty; S Stringer; E Cruz; Leticia Medina-Gundrum; Steven D Weitman
Elevated expression of DNA ligase I in human cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):4143-8.
2001: Li Liu; Neha Vapiwala; L K Munoz; Naomi J Winick; Steven D Weitman; L C Strauss; L S Frankel; David I Rosenthal
A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors.
Medical and pediatric oncology 2001;37(4):390-2.
2001: Gaylen Zentner; R Rathi; C Shih; James C. McRea; M H Seo; H Oh; B G Rhee; J Mestecky; Z Moldoveanu; M Morgan; Steven D Weitman
Biodegradable block copolymers for delivery of proteins and water-insoluble drugs.
Journal of controlled release : official journal of the Controlled Release Society 2001;72(1-3):203-15.
2001: Lisa A Hammond; K Davidson; R Lawrence; Jim B Camden; Daniel Von Hoff; Steven D Weitman; Elzbieta Izbicka
Exploring the mechanisms of action of FB642 at the cellular level.
Journal of cancer research and clinical oncology 2001;127(5):301-13.
2001: Jon I Williams; Steven D Weitman; C M Gonzalez; C H Jundt; J Marty; S D Stringer; Kenneth J Holroyd; McLane Michael; Qiming Chen; Michael Zasloff; Daniel Von Hoff
Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):724-33.
2001: Susan Blaney; Stacey L Berg; C Pratt; Steven D Weitman; J Sullivan; Lori Luchtman-Jones; Mark Bernstein
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(1):32-7.
2000: S Gail Eckhardt; Sharyn D Baker; Carolyn D Britten; Manuel Hidalgo; Lillian Siu; Lisa A Hammond; Miguel A Villalona-Calero; Sally A Felton; Ronald L Drengler; John Kuhn; Gary M Clark; S L Smith; John R MacDonald; C Smith; Judy Moczygemba; Steven D Weitman; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Lisa A Hammond; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Steven D Weitman; H Barrera; R Moore; C Gonzalez; Jennifer Marty; Susan G Hilsenbeck; John R MacDonald; Stephen J Waters; Daniel Von Hoff
MGI 114: augmentation of antitumor activity when combined with topotecan.
Journal of pediatric hematology/oncology 2000;22(4):306-14.
2000: Steven D Weitman; J Marty; J Jolivet; C Locas; Daniel Von Hoff
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1574-8.
2000: Dirk B Mendel; A Douglas Laird; Beverly D Smolich; Robert Blake; Congxin Liang; Alison L Hannah; R M Shaheen; L M Ellis; Steven D Weitman; Laura K Shawver; Julie M Cherrington
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
Anti-cancer drug design 2000;15(1):29-41.
1999: Manuel Hidalgo; Elzbieta Izbicka; S Gail Eckhardt; J R MacDonald; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Steven D Weitman; Anne-Marie Langevin; R L Berkow; Paul Thomas; C A Hurwitz; Andrew Kraft; R L Dubowy; D L Smith; Mark Bernstein
A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2344-8.
1999: RA Lawrence; Elzbieta Izbicka; R L De Jager; A Tohgo; G M Clark; Steven D Weitman; eric rowinsky; Daniel Von Hoff
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Anti-cancer drugs 1999;10(7):655-61.
1999: Randy M Wadkins; Philip Potter; B Vladu; Jennifer Marty; Gina L Mangold; Steven D Weitman; Govindarajan Manikumar; Mansukh C Wani; Monroe E Wall; Daniel Von Hoff
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Cancer research 1999;59(14):3424-8.
1999: T Petit; Elzbieta Izbicka; RA Lawrence; W R Bishop; Steven D Weitman; Daniel Von Hoff
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):449-53.
1999: T Petit; Elzbieta Izbicka; RA Lawrence; C Nalin; Steven D Weitman; Daniel Von Hoff
Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.
Anti-cancer drugs 1999;10(3):309-15.
1999: Sami Diab; Susan G Hilsenbeck; Elzbieta Izbicka; Steven D Weitman; Daniel Von Hoff
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.
Anti-cancer drugs 1999;10(3):303-7.
1999: Manuel Hidalgo; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Anti-cancer drugs 1999;10(3):295-302.
1999: Carolyn D Britten; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Cancer research 1999;59(5):1049-53.
1999: Carolyn D Britten; Elzbieta Izbicka; Susan G Hilsenbeck; R Lawrence; K Davidson; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Cancer chemotherapy and pharmacology 1999;44(2):105-10.
1999: Steven D Weitman; Gina L Mangold; Jennifer Marty; D Dexter; Susan G Hilsenbeck; J Rake; P Juniewicz; Daniel Von Hoff
Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Cancer chemotherapy and pharmacology 1999;43(5):402-8.
1998: S Shah; Steven D Weitman; Anne-Marie Langevin; Mark Bernstein; Wayne L Furman; C Pratt
Phase I therapy trials in children with cancer.
Journal of pediatric hematology/oncology 1998;20(5):431-8.
1998: Anne-Marie Langevin; D T Casto; Paul Thomas; Steven D Weitman; Cynthia Kretschmar; Holcombe E Grier; C Pratt; R Dubowy; Mark Bernstein; Susan Blaney; Teresa J Vietti
Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2494-9.
1998: Barbara A Gruner; Thomas S DeNapoli; W Andrews; Gail Tomlinson; L Bowman; Steven D Weitman
Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis.
Journal of pediatric hematology/oncology 1998;20(3):274-8.
1998: Steven D Weitman; R Moore; H Barrera; Nai-Kong V Cheung; Elzbieta Izbicka; Daniel Von Hoff
In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
Journal of pediatric hematology/oncology 1998;20(2):136-9.
1998: Barbara A Gruner; Steven D Weitman
The folate receptor as a potential therapeutic anticancer target.
Investigational new drugs 1998;16(3):205-19.
1998: L Carlson; Marshall P Goren; Dorothy A Bush; James C Griener; Raymond Quigley; I Tkaczewski; Barton A. Kamen; Steven D Weitman
Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor.
Cancer chemotherapy and pharmacology 1998;41(2):140-6.
1997: Steven D Weitman; S Ochoa; J Sullivan; J Shuster; Naomi J Winick; C Pratt; Teresa J Vietti; M Harris
Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study.
Journal of pediatric hematology/oncology 1997;19(3):187-91.
1996: L Carlson; P Ho; M Smith; J Reisch; Steven D Weitman
Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials.
Journal of pediatric hematology/oncology 1996;18(3):250-6.
1996: Steven D Weitman; L Carlson; C B Pratt
New drug development for pediatric oncology.
Investigational new drugs 1996;14(1):1-10.
1994: Steven D Weitman; Naomi J Winick; Barton A. Kamen
"Above all do no harm:" horizons in pediatric oncology.
Current opinion in pediatrics 1994;6(2):219-23.
1994: Barton A. Kamen; Steven D Weitman
High-dose methotrexate: is it warranted?
Pediatric hematology and oncology 1994;11(2):135-7.
1994: J K Whipple; K S Lewis; Steven D Weitman; R K Ausman; D W Bourne; W Andrews; M B Adams; E A Sasse; E J Quebbeman
Pharmacokinetic evaluation of a new oral cyclosporine formulation.
Pharmacotherapy 1994;14(1):105-10.
1994: Steven D Weitman; K M Frazier; Barton A. Kamen
The folate receptor in central nervous system malignancies of childhood.
Journal of neuro-oncology 1994;21(2):107-12.
1993: C A Hurwitz; Mary Relling; Steven D Weitman; Yaddanapudi Ravindranath; T J Vietti; D R Strother; A H Ragab; Charles B Pratt
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(12):2324-9.
1993: D W Fort; R H Lark; A K Smith; M Marling-Cason; Steven D Weitman; B Shane; Barton A. Kamen
Accumulation of 5-methyltetrahydrofolic acid and folylpolyglutamate synthetase expression by mitogen stimulated human lymphocytes.
British journal of haematology 1993;84(4):595-601.
1993: Steven D Weitman; E Glatstein; Barton A. Kamen
Back to the basics: the importance of concentration x time in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):820-1.
1993: Mahmoud M Mustafa; Steven D Weitman; Naomi J Winick; William Joseph Bellini; Charles F Timmons; J D Siegel
Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(5):654-60.
1992: Steven D Weitman; Arthur G Weinberg; L R Coney; V R Zurawski; D S Jennings; Barton A. Kamen
Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis.
Cancer research 1992;52(23):6708-11.
1992: Steven D Weitman; R H Lark; L R Coney; D W Fort; Verna Frasca; V R Zurawski; Barton A. Kamen
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.
Cancer research 1992;52(12):3396-401.
1991: Steven D Weitman; G R Buchanan; Barton A. Kamen
Pulmonary toxicity of deferoxamine in children with advanced cancer.
Journal of the National Cancer Institute 1991;83(24):1834-5.
1991: Steven D Weitman; Barton A. Kamen
Fosfomycin--friend or foe?
Pediatric hematology and oncology 1991;8(3):vii-viii.
1991: Steven D Weitman; Gregory Kato ; J L Barbosa; Barton A. Kamen
Low-dose methotrexate therapy for hepatoblastoma.
Cancer chemotherapy and pharmacology 1991;28(3):233-4.
1990: Steven D Weitman; W Andrews; E Quebbeman; J Whipple; R Ausman; W Schulte; M Adams
A new cyclosporine formulation.
Transplantation 1990;50(6):1087.
1989: Steven D Weitman; A M Phelan; J J Lech; D G Lange
Propranolol-induced alterations in rat erythrocyte membrane fluidity and apparent phase-transition temperatures. A depth-dependent process.
Biochemical pharmacology 1989;38(18):2949-55.
1987: K C Preuss; Steven D Weitman
Determination of in utero fetal rat heart rate by ultrasound.
Journal of pharmacological methods 1987;17(1):59-65.
1986: Steven D Weitman; M J Vodicnik; J J Lech
Influence of pregnancy on the hepatic metabolism of parathion.
Developmental pharmacology and therapeutics 1986;9(1):23-31.
1986: Steven D Weitman; M J Vodicnik; J J Lech
Mechanism of enhanced parathion/paraoxon toxicity during pregnancy in the mouse.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1986;6(1):155-61.
1983: Steven D Weitman; M J Vodicnik; J J Lech
Influence of pregnancy on parathion toxicity and disposition.
Toxicology and applied pharmacology 1983;71(2):215-24.
1982: A H Glickman; Steven D Weitman; J J Lech
Differential toxicity of trans-permethrin in rainbow trout and mice. I. Role of biotransformation.
Toxicology and applied pharmacology 1982;66(2):153-61.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.